<DOC>
	<DOC>NCT01604057</DOC>
	<brief_summary>This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.</brief_summary>
	<brief_title>Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal Females Age ≥ 45 years. Weight &gt; 45 kg and &lt; 90 kg Normal nasal examination at baseline. Low bone mass at lumbar spine, total hip or femoral neck (BMD Tscore of ≤ 1.5 or lower) or a recent (within 5 years of baseline) history of fragility fracture (excluding fractures of hands, feet, face and/or skull) and a Tscore of 1.0 or lower at lumbar spine, total hip or femoral neck Serious Medical Condition History of diseases which affect bone metabolism other than postmenopausal osteoporosis such as Paget's disease, any secondary causes of osteoporosis, hypoparathyroidism, or hyperparathyroidism Have a history of cancer within the past 5 years, except for basal cell carcinoma Have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney stones or preexisting hypercalciuria; Have used any of the mostly commonly prescribed osteoporosis medications within 3 months of starting the investigational product, or for more than 1 month at any time within 6 months prior to starting investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>